Charles Smith
Endocrinology, Diabetes & Metabolism · Canton, OHNPI 1578516647
Payments from drug & device makers
$5,348,454in general payments, 2019–2025
Across 2,071 payments — averaging $2582.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$5.2M
- Takeda Pharmaceuticals U.S.A., Inc.$105K
- Amgen$119
- Phathom Pharmaceuticals, Inc.$99
- Pfizer$91
- Insulet Corporation$18
General payments by program year
19
20
22
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 2,046 | $5,242,888 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $105,239 |
| Amgen | 1 | $119 |
| Phathom Pharmaceuticals, Inc. | 1 | $99 |
| Pfizer | 6 | $91 |
| Insulet Corporation | 1 | $18 |
How this compares
$5,348,454 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Other endocrinology, diabetes & metabolism in Canton
- Arvind KrishnaCanton$3.1M
- Kevin WietechaCanton$127K
- Toby BriskinBedford$9.8M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- John PaesWesterville$671K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.